Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed. | Neoplasma;64(4): 605-610, 2017. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed.

Fiala, O; Hosek, P; Pesek, M; Finek, J; Racek, J; Buchler, T; Poprach, A; Hejduk, K; Chloupkova, R; Sorejs, O; Ecksteinova, M; Vitovec, M; Cizkova, K; Kucera, R; Topolcan, O.

Neoplasma ; 64(4): 605-610, 2017.

Article in En | MEDLINE | ID: mdl-28485168

Subject(s)
Key words

C-reactive protein; NSCLC; chemotherapy; lung cancer; pemetrexed prognosis.

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: C-Reactive Protein / Carcinoma, Non-Small-Cell Lung / Pemetrexed / Lung Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Neoplasma Year: 2017 Document type: Article Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: C-Reactive Protein / Carcinoma, Non-Small-Cell Lung / Pemetrexed / Lung Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Neoplasma Year: 2017 Document type: Article Country of publication: